{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:32:35Z","timestamp":1785439955584,"version":"3.56.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1124\/dmd.111.039917","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T01:31:41Z","timestamp":1304472701000},"page":"1321-1323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prolonged Toxic Effects After Cocaine Challenge in Butyrylcholinesterase\/Plasma Carboxylesterase Double Knockout Mice: A Model for Butyrylcholinesterase-Deficient Humans"],"prefix":"10.1016","volume":"39","author":[{"given":"Ellen G.","family":"Duysen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Lockridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.039917_bib1","first-page":"1086","article-title":"DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites","volume":"50","author":"Bartels","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1124\/dmd.111.039917_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/ajem.2000.9282","article-title":"Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED","volume":"18","author":"Blaho","year":"2000","journal-title":"Am J Emerg Med"},{"key":"10.1124\/dmd.111.039917_bib3","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/sj.npp.1301666","article-title":"A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats","volume":"33","author":"Brimijoin","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/dmd.111.039917_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1742-7843.2008.00259.x","article-title":"Increased hepatotoxicity and cardiac fibrosis in cocaine-treated butyrylcholinesterase knockout mice","volume":"103","author":"Duysen","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.111.039917_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cbi.2008.04.024","article-title":"An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties","volume":"175","author":"Gao","year":"2008","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.111.039917_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0196-0644(05)80883-2","article-title":"Association between life-threatening cocaine toxicity and plasma cholinesterase activity","volume":"21","author":"Hoffman","year":"1992","journal-title":"Ann Emerg Med"},{"key":"10.1124\/dmd.111.039917_bib7","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/dmd.111.039917_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1520\/JFS16087J","article-title":"Relating cocaine blood concentrations to toxicity\u2014an autopsy study of 99 cases","volume":"43","author":"Karch","year":"1998","journal-title":"J Forensic Sci"},{"key":"10.1124\/dmd.111.039917_bib9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/jpet.107.133330","article-title":"The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency","volume":"324","author":"Li","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.039917_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.111.039917_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0163-7258(90)90044-3","article-title":"Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine","volume":"47","author":"Lockridge","year":"1990","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.111.039917_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008571-199508000-00001","article-title":"Pharmacogenetics of cocaine: a critical review","volume":"5","author":"Morse","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.111.039917_bib13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-8703(93)90122-P","article-title":"Medical complications of cocaine: possible relationship to low plasma cholinesterase enzyme","volume":"125","author":"Om","year":"1993","journal-title":"Am Heart J"},{"key":"10.1124\/dmd.111.039917_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s002040000154","article-title":"Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes","volume":"74","author":"Pellinen","year":"2000","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.111.039917_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1042\/bst0310620","article-title":"Human carboxylesterase 1: from drug metabolism to drug discovery","volume":"31","author":"Redinbo","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/dmd.111.039917_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0026-895X(24)23159-X","article-title":"An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient","volume":"55","author":"Xie","year":"1999","journal-title":"Mol Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624058215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624058215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.039917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:43:49Z","timestamp":1739904229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624058215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0090955624058215"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.039917","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged Toxic Effects After Cocaine Challenge in Butyrylcholinesterase\/Plasma Carboxylesterase Double Knockout Mice: A Model for Butyrylcholinesterase-Deficient Humans","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.039917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}